Orito E, Mizokami M
Second Department of Internal Medicine, Nagoya City University Medical School.
Nihon Rinsho. 1994 Jul;52(7):1754-8.
It has been reported that pre-treatment serum HCV RNA levels was important predicting factors to subsequent interferon therapy (Orito et al.). In this report, HCV genotype and serum HCV RNA level were determined using PCR and bDNA assay in patients who received interferon-alfa 2b. Patients with genotype III HCV responded more favorably in complete and sustained response than genotype II HCV. A higher proportion of patients who had low pre-treatment serum HCV RNA level responded in complete and sustained fashion. When patients with high or low level viremia were compared, significantly higher proportion of the patients with low level HCV RNA showed sustained response irrespective of HCV genotype.
据报道，治疗前血清丙型肝炎病毒（HCV）RNA水平是后续干扰素治疗的重要预测因素（折户等人）。在本报告中，使用聚合酶链反应（PCR）和分支DNA（bDNA）分析方法，对接受α-2b干扰素治疗的患者测定了HCV基因型和血清HCV RNA水平。与HCV基因型II的患者相比，HCV基因型III的患者在完全缓解和持续缓解方面反应更佳。治疗前血清HCV RNA水平低的患者中，以完全和持续方式缓解的比例更高。当比较高病毒血症水平和低病毒血症水平的患者时，无论HCV基因型如何，HCV RNA水平低的患者持续缓解的比例显著更高。
